JP2019505545A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505545A5
JP2019505545A5 JP2018543286A JP2018543286A JP2019505545A5 JP 2019505545 A5 JP2019505545 A5 JP 2019505545A5 JP 2018543286 A JP2018543286 A JP 2018543286A JP 2018543286 A JP2018543286 A JP 2018543286A JP 2019505545 A5 JP2019505545 A5 JP 2019505545A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
seq
cell
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505545A (ja
JP6987068B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/060974 external-priority patent/WO2017083296A1/en
Publication of JP2019505545A publication Critical patent/JP2019505545A/ja
Publication of JP2019505545A5 publication Critical patent/JP2019505545A5/ja
Priority to JP2021194050A priority Critical patent/JP7335937B2/ja
Application granted granted Critical
Publication of JP6987068B2 publication Critical patent/JP6987068B2/ja
Priority to JP2023133443A priority patent/JP7646759B2/ja
Priority to JP2025034156A priority patent/JP2025098050A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018543286A 2015-11-09 2016-11-08 癌マーカーおよび治療標的としてのグリピカン２ Active JP6987068B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021194050A JP7335937B2 (ja) 2015-11-09 2021-11-30 癌マーカーおよび治療標的としてのグリピカン２
JP2023133443A JP7646759B2 (ja) 2015-11-09 2023-08-18 癌マーカーおよび治療標的としてのグリピカン２
JP2025034156A JP2025098050A (ja) 2015-11-09 2025-03-05 癌マーカーおよび治療標的としてのグリピカン２

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562253000P 2015-11-09 2015-11-09
US62/253,000 2015-11-09
US201662350976P 2016-06-16 2016-06-16
US62/350,976 2016-06-16
PCT/US2016/060974 WO2017083296A1 (en) 2015-11-09 2016-11-08 Glypican 2 as a cancer marker and therapeutic target

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021194050A Division JP7335937B2 (ja) 2015-11-09 2021-11-30 癌マーカーおよび治療標的としてのグリピカン２

Publications (3)

Publication Number Publication Date
JP2019505545A JP2019505545A (ja) 2019-02-28
JP2019505545A5 true JP2019505545A5 (enExample) 2019-12-12
JP6987068B2 JP6987068B2 (ja) 2021-12-22

Family

ID=58695360

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018543286A Active JP6987068B2 (ja) 2015-11-09 2016-11-08 癌マーカーおよび治療標的としてのグリピカン２
JP2021194050A Active JP7335937B2 (ja) 2015-11-09 2021-11-30 癌マーカーおよび治療標的としてのグリピカン２
JP2023133443A Active JP7646759B2 (ja) 2015-11-09 2023-08-18 癌マーカーおよび治療標的としてのグリピカン２
JP2025034156A Pending JP2025098050A (ja) 2015-11-09 2025-03-05 癌マーカーおよび治療標的としてのグリピカン２

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021194050A Active JP7335937B2 (ja) 2015-11-09 2021-11-30 癌マーカーおよび治療標的としてのグリピカン２
JP2023133443A Active JP7646759B2 (ja) 2015-11-09 2023-08-18 癌マーカーおよび治療標的としてのグリピカン２
JP2025034156A Pending JP2025098050A (ja) 2015-11-09 2025-03-05 癌マーカーおよび治療標的としてのグリピカン２

Country Status (16)

Country Link
US (2) US11814440B2 (enExample)
EP (2) EP4382127A3 (enExample)
JP (4) JP6987068B2 (enExample)
AU (2) AU2016354440B2 (enExample)
CA (1) CA3004438A1 (enExample)
DK (1) DK3373968T5 (enExample)
ES (1) ES2982393T3 (enExample)
FI (1) FI3373968T3 (enExample)
HU (1) HUE067793T2 (enExample)
LT (1) LT3373968T (enExample)
PL (1) PL3373968T3 (enExample)
PT (1) PT3373968T (enExample)
RS (1) RS65666B1 (enExample)
SI (1) SI3373968T1 (enExample)
SM (1) SMT202400295T1 (enExample)
WO (1) WO2017083296A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004438A1 (en) * 2015-11-09 2017-05-18 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
CA3031559A1 (en) * 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
EP3549597A1 (en) * 2018-04-06 2019-10-09 Heinrich-Heine-Universität Düsseldorf Synthetic signalling constructs and its use
AU2019317565A1 (en) * 2018-08-08 2021-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
EP3965897A4 (en) * 2019-05-07 2023-01-04 The Board of Trustees of the Leland Stanford Junior University CHEMERA ANTIGEN RECEPTORS TARGETING GLYPICAN-2
AU2020317009A1 (en) * 2019-07-19 2022-02-03 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors containing Glypican 2 binding domains

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
BR9306802A (pt) 1992-07-27 1998-12-08 Pioneer Hi Bred Int Processo independente de genótipos para produção de planta de soja transgénica e processo de regeneração de plantas de soja a partir de nodos cotiledonais
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
PT781343E (pt) 1994-09-08 2003-11-28 Vision 7 Gmbh Hibridos de vectores retrovirais e sua utilizacao para transferencia genetica
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
ES2312586T3 (es) * 2001-06-22 2009-03-01 Chugai Seiyaku Kabushiki Kaisha Inhibidor del crecimiento celular que contenga un anticuerpo anti-clipicano 3.
KR20130103580A (ko) * 2004-08-24 2013-09-23 추가이 세이야쿠 가부시키가이샤 항 글리피칸 3 항체를 이용한 어쥬번트 요법
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
JP2017513854A (ja) 2014-04-15 2017-06-01 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｗｉｓｐ１に結合する抗原結合タンパク質
CN108603170A (zh) * 2015-06-12 2018-09-28 莱蒂恩技术公司 用工程改造的t细胞治疗癌症的方法
CA3004438A1 (en) 2015-11-09 2017-05-18 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
CA3031559A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof

Similar Documents

Publication Publication Date Title
JP2019505545A5 (enExample)
JP7438958B2 (ja) 新規な抗体分子、その調製方法及びその使用
JP6708635B2 (ja) ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
EP3130607B1 (en) Muc1* antibodies
CA3199830A1 (en) Tumor-specific claudin 18.2 antibody-drug conjugates
JP2019523630A5 (enExample)
JP2021502104A5 (enExample)
CN112074534A (zh) 双特异性抗原结合分子
US20240342283A1 (en) ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors
JP2020510422A5 (enExample)
CN101583625A (zh) 抗-cd16结合分子
WO2018119118A4 (en) Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
JP2018046811A (ja) 異常細胞を標的とする多重特異性結合分子
JP2005507635A5 (enExample)
FI3373968T3 (fi) Glypikaani 2 syövän merkkiaineena ja terapeuttisena kohteena
Luo et al. Design and applications of bispecific heterodimers: molecular imaging and beyond
CN116940598A (zh) 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
WO2023071676A1 (zh) 一种抗her2/抗pd-l1双功能抗体及其应用
Hayashi et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells
JP2021501575A (ja) 二重特異性抗体並びにその製造方法及び使用方法
SI2943510T1 (en) New fragments of antibodies, compositions and their use
US20250375530A1 (en) Ror1/egfr bi-specific antigen binding molecules
AU2021446021A1 (en) Anti-bcam antibody or antigen-binding fragment thereof
Korn et al. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes
Asano et al. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells